Survivors Have Heart Essay Contest calls on
heart attack survivors to submit their stories for the opportunity
to educate and inspire other survivors at an event hosted by Bob
Harper
Bob Harper, celebrity personal trainer, author and heart attack
survivor, is teaming up with AstraZeneca to help people like him
who have experienced a heart attack share their stories to educate
and inspire others. Today, AstraZeneca is partnering with the
nationally recognized fitness expert and TV personality to launch
Survivors Have Heart, an essay contest where heart attack survivors
can share personal stories of their journey and connect with other
survivors, including Bob Harper.
Bob Harper and AstraZeneca are asking those who have had a heart
attack to visit www.survivorshaveheart.com and submit an essay of
500 words or less about their experience and recovery. Five stories
from heart attack survivors will be chosen and those selected,
along with a caregiver of their choice, will travel to New York
City to be inducted into a heart attack survivor’s network. There
they will have the opportunity to join Bob Harper in celebrating
survivorship and helping those who may be at risk of another heart
attack to understand the warning signs and take the necessary steps
toward living a healthier life.
Bob Harper said: “This partnership with AstraZeneca is very
personal to me as a heart attack survivor. My life’s mission has
been rooted in living a healthy lifestyle, and I thought I was
doing everything right. I never thought I would experience a heart
attack. Being a heart attack survivor adds you to a club you never
want to join, but once you are a part of it, you feel bonded by the
experience. As survivors, we carry each other and together, with
the support of networks like Survivors Have Heart, we can make a
meaningful difference in raising awareness on how to navigate this
complex journey.”
Harper suffered a severe heart attack in February 2017 that
forever changed his life. With a commitment to his recovery, Harper
has since focused on getting his life, health and fitness back on
track. In addition to making lifestyle changes and following his
doctor’s treatment plan, Harper was prescribed BRILINTA®
(ticagrelor) 90 mg tablets, made by AstraZeneca, to help reduce the
risk of having another heart attack or dying from one. BRILINTA is
indicated to reduce the rate of cardiovascular death, myocardial
infarction (MI, also known as a heart attack), and stroke in
patients with acute coronary syndrome (ACS).
Rod Wooten, Vice President, Cardiovascular and Metabolic
Diseases (CVMD), AstraZeneca, said: “Stories like Bob’s sit at the
foundation of AstraZeneca’s commitment to addressing patient needs
to help make a meaningful difference through health, education and
support. This partnership embodies our belief that we must continue
to play an active role in raising awareness and educating patients
on important steps they can take to reduce their risk following
another heart attack.”
This year, an estimated 790,000 Americans will experience a
heart attack. The partnership with AstraZeneca will allow Bob
Harper to share his story and provide tips and basic steps patients
can take to help maintain a healthy life, while also following
their treatment plan to help reduce their risk of having another
heart attack.
Donnette Smith, President of community-based nonprofit, Mended
Hearts Inc, said: “Mended Hearts is an organization with a strong
focus on providing peer-to-peer support for patients across the
cardiovascular treatment landscape and we want to recognize the
important work that AstraZeneca and Bob Harper are doing in hopes
that it will empower more patients to speak up and build their
support network following their heart attack. It is critical for
patients to ensure they take an active role in their recovery and
feel pride in the steps they are taking as heart attack
survivors.”
The Survivors Have Heart Essay Contest will run from November
30, 2017 – January 15, 2018. For complete details and to enter
please visit: www.survivorshaveheart.com.
IMPORTANT SAFETY INFORMATION FOR
BRILINTA® (ticagrelor) 60-MG AND 90-MG
TABLETS
WARNING: (A) BLEEDING RISK, (B) ASPIRIN DOSE AND BRILINTA
EFFECTIVENESS
A. BLEEDING RISK
- BRILINTA, like other antiplatelet
agents, can cause significant, sometimes fatal bleeding
- Do not use BRILINTA in patients with
active pathological bleeding or a history of intracranial
hemorrhage
- Do not start BRILINTA in patients
undergoing urgent coronary artery bypass graft surgery
- If possible, manage bleeding without
discontinuing BRILINTA. Stopping BRILINTA increases the risk of
subsequent cardiovascular events
B. ASPIRIN DOSE AND BRILINTA EFFECTIVENESS
- Maintenance doses of aspirin above
100 mg reduce the effectiveness of BRILINTA and should be
avoided
CONTRAINDICATIONS
- BRILINTA is contraindicated in patients
with a history of intracranial hemorrhage or active pathological
bleeding such as peptic ulcer or intracranial hemorrhage. BRILINTA
is also contraindicated in patients with hypersensitivity (eg,
angioedema) to ticagrelor or any component of the product
WARNINGS AND PRECAUTIONS
- Dyspnea was reported in about 14% of
patients treated with BRILINTA, more frequently than in patients
treated with control agents. Dyspnea resulting from BRILINTA is
often self-limiting
- Discontinuation of BRILINTA will
increase the risk of MI, stroke, and death. When possible,
interrupt therapy with BRILINTA for 5 days prior to surgery that
has a major risk of bleeding. If BRILINTA must be temporarily
discontinued, restart as soon as possible
- Ticagrelor can cause ventricular
pauses. Bradyarrhythmias including AV block have been reported in
the post-marketing setting. PLATO and PEGASUS excluded patients at
increased risk of bradyarrhythmias not protected by a pacemaker,
and they may be at increased risk of developing bradyarrhythmias
with ticagrelor
- Avoid use of BRILINTA in patients with
severe hepatic impairment. Severe hepatic impairment is likely to
increase serum concentration of ticagrelor and there are no studies
of BRILINTA in these patients
ADVERSE REACTIONS
- The most common adverse reactions
associated with the use of BRILINTA included bleeding and dyspnea:
In PLATO, for BRILINTA vs clopidogrel, non-CABG PLATO-defined major
bleeding (3.9% vs 3.3%) and dyspnea (14% vs 8%); in PEGASUS,
BRILINTA vs aspirin alone, TIMI Total Major bleeding (1.7% vs 0.8%)
and dyspnea (14% vs 6%)
DRUG INTERACTIONS
- Avoid use with strong CYP3A inhibitors
and strong CYP3A inducers. BRILINTA is metabolized by CYP3A4/5.
Strong inhibitors substantially increase ticagrelor exposure and so
increase the risk of adverse events. Strong inducers substantially
reduce ticagrelor exposure and so decrease the efficacy of
ticagrelor
- Patients receiving more than 40 mg per
day of simvastatin or lovastatin may be at increased risk of
statin-related adverse events
- Monitor digoxin levels with initiation
of, or change in, BRILINTA therapy
INDICATIONS
BRILINTA® (ticagrelor) tablets are indicated to reduce the rate
of cardiovascular death, myocardial infarction (MI), and stroke in
patients with acute coronary syndrome (ACS) or a history of
myocardial infarction. For at least the first 12 months following
ACS, it is superior to clopidogrel.
BRILINTA also reduces the rate of stent thrombosis in patients
who have been stented for treatment of ACS.
DOSING
In the management of ACS, initiate BRILINTA treatment with a
180-mg loading dose. Administer 90 mg twice daily during the first
year after an ACS event. After one year administer 60 mg twice
daily. Use BRILINTA with a daily maintenance dose of aspirin of
75-100 mg.
Please read Medication Guide
and Prescribing Information, including
Boxed WARNINGS, for BRILINTA.
NOTES TO EDITORS
About AstraZeneca in Cardiovascular, Renal & Metabolic
Diseases (CVMD)
Cardiovascular, renal and metabolic diseases together form one
of AstraZeneca’s main therapy areas and platforms for future
growth. By following the science to understand more clearly the
underlying links between the heart, kidney and pancreas,
AstraZeneca is investing in a portfolio of medicines to protect
organs and improve outcomes by slowing disease progression,
reducing risks and tackling co-morbidities. Our ambition is to
modify or halt the natural course of CVMDs and even regenerate
organs and restore function, by continuing to deliver
transformative science that improves treatment practices and CVMD
health for millions of patients worldwide.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialization of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular & Metabolic
Diseases and Respiratory. The Company also is selectively active in
the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. For more information,
please visit www.astrazeneca-us.com and follow us on
Twitter @AstraZenecaUS.
US-16246 Last Updated 11/17
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171130005199/en/
AstraZenecaMedia InquiriesMichele Meixell, +1
302-885-2677Abigail Bozarth, +1 302-885-2677
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024